The median OSLM of the patients with EGFR-mutated NSCLC included in this study was 13.0 months, ranging from 0.5 to 42.0 months (95% CI = 9.067–16.933), with 64.2% maturity (34/53; Figure 3). This evidence concerns the gene EGFR and non-small cell lung carcinoma.